Your browser doesn't support javascript.
Durability and cross-reactivity of immune responses induced by a plant-based virus-like particle vaccine for COVID-19.
Gobeil, Philipe; Pillet, Stéphane; Boulay, Iohann; Charland, Nathalie; Lorin, Aurélien; Cheng, Matthew P; Vinh, Donald C; Boutet, Philippe; Van Der Most, Robbert; Roman, François; Ceregido, Maria Angeles; Landry, Nathalie; D'Aoust, Marc-André; Ward, Brian J.
  • Gobeil P; Medicago Inc., Suite 600, 1020 route de l'Église, Québec, QC, G1V 3V9, Canada.
  • Pillet S; Medicago Inc., Suite 600, 1020 route de l'Église, Québec, QC, G1V 3V9, Canada.
  • Boulay I; Medicago Inc., Suite 600, 1020 route de l'Église, Québec, QC, G1V 3V9, Canada.
  • Charland N; Medicago Inc., Suite 600, 1020 route de l'Église, Québec, QC, G1V 3V9, Canada.
  • Lorin A; Medicago Inc., Suite 600, 1020 route de l'Église, Québec, QC, G1V 3V9, Canada.
  • Cheng MP; The Research Institute of the McGill University Health Centre, 1001 Decarie Street, Montreal, QC, H4A 3J1, Canada.
  • Vinh DC; The Research Institute of the McGill University Health Centre, 1001 Decarie Street, Montreal, QC, H4A 3J1, Canada.
  • Boutet P; GlaxoSmithKline (Vaccines), Avenue Fleming 20, 1300, Wavre, Belgium.
  • Van Der Most R; GlaxoSmithKline (Vaccines), rue de l'Institut 89, 1330, Rixensart, Belgium.
  • Roman F; BioNTech, An der Goldgrube 12, 55131, Mainz, Germany.
  • Ceregido MA; GlaxoSmithKline (Vaccines), Avenue Fleming 20, 1300, Wavre, Belgium.
  • Landry N; GlaxoSmithKline (Vaccines), Avenue Fleming 20, 1300, Wavre, Belgium.
  • D'Aoust MA; Medicago Inc., Suite 600, 1020 route de l'Église, Québec, QC, G1V 3V9, Canada.
  • Ward BJ; Medicago Inc., Suite 600, 1020 route de l'Église, Québec, QC, G1V 3V9, Canada.
Nat Commun ; 13(1): 6905, 2022 Nov 12.
Article in English | MEDLINE | ID: covidwho-2118465
ABSTRACT
As the SARS-CoV-2 pandemic evolves, vaccine evaluation needs to include consideration of both durability and cross-reactivity. This report expands on previously reported results from a Phase 1 trial of an AS03-adjuvanted, plant-based coronavirus-like particle (CoVLP) displaying the spike (S) glycoprotein of the ancestral SARS-CoV-2 virus in healthy adults (NCT04450004). Humoral and cellular responses against the ancestral strain were evaluated 6 months post-second dose (D201) as secondary outcomes. Independent of dose, all vaccinated individuals retain binding antibodies, and ~95% retain neutralizing antibodies (NAb). Interferon gamma and interleukin-4 responses remain detectable in ~94% and ~92% of vaccinees respectively. In post-hoc analyses, variant-specific (Alpha, Beta, Delta, Gamma and Omicron) NAb were assessed at D42 and D201. Using a live virus neutralization assay, broad cross-reactivity is detectable against all variants at D42. At D201, cross-reactive antibodies are detectable in almost all participants against Alpha, Gamma and Delta variants (94%) and the Beta variant (83%) and in a smaller proportion against Omicron (44%). Results are similar with the pseudovirion assay. These data suggest that two doses of 3.75 µg CoVLP+AS03 elicit a durable and cross-reactive response that persists for at least 6 months post-vaccination.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / Vaccines, Virus-Like Particle / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-34728-1

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / Vaccines, Virus-Like Particle / COVID-19 Type of study: Experimental Studies / Randomized controlled trials Topics: Vaccines / Variants Limits: Adult / Humans Language: English Journal: Nat Commun Journal subject: Biology / Science Year: 2022 Document Type: Article Affiliation country: S41467-022-34728-1